A number of online resources are available for people living with pulmonary arterial hypertension (PAH). The links below provide additional education, resources, and support.
Emotional and Practical Support
If you are a PAH patient who is considering Tyvaso or has already started Tyvaso, the PEER Network may be for you. Through the PEER Network, new patients can connect with someone who is already taking Tyvaso. Experienced Tyvaso patients volunteer their time to share lifestyle information and provide emotional support to help new patients. United Therapeutics sponsors the PEER Network so that new patients can have private, one-on-one communication to learn more about what it's really like to take Tyvaso.
For more information, visit www.peernetwork.net or call 1-866-505-PEER.
PAH Disease Education
Living PAH is a program designed to empower patients — and their loved-ones — with PAH disease information and lifestyle tips. Living PAH programs, educational resources, tools and support can help you learn all you can about PAH, monitor your condition and make informed choices in your care. United Therapeutics proudly sponsors the Living PAH program and there is no cost for any of the Living PAH resources.
For more information, visit www.livingpah.com.
Pulmonary Hypertension Association (PHA)
PHA is a leading community-based organization for patients with PAH. Its mission is to find ways to prevent and cure PAH while providing hope to the pulmonary hypertension community through support, education, advocacy and awareness.
phaware provides digital content focused on education, resources, and knowledge for PH patients, caregivers, and medical professionals.
National Heart, Lung, and Blood Institute (NHLBI)
NHLBI is part of the National Institutes of Health (NIH), the agency of the US Department of Health and Human Services that is largely responsible for conducting medical research. The NHLBI website has easy-to-understand information about various diseases that affect the heart and lungs. To learn more about PAH, visit www.nhlbi.nih.gov and search for PAH.
National Organization of Rare Diseases (NORD)
The NORD offers programs and services for patients who have been diagnosed with rare conditions and diseases.
There are a number of financial assistance programs available to help you obtain your medication, should you qualify. To learn more about the programs, call 1-877-UNITHER (1-877-864-8437).
IMPORTANT SAFETY INFORMATION FOR TYVASO
- Tyvaso is breathed in (inhalable) through your mouth into your lungs. Tyvaso should only be used with the Tyvaso Inhalation System.
Before you take Tyvaso, tell your healthcare provider about all of your medical conditions, including if you:
- Have a lung disease (such as asthma or chronic obstructive pulmonary disease (COPD)).
- Have a lung infection.
- Have liver or kidney problems, as your ability to tolerate Tyvaso may be affected.
- Have low blood pressure, as Tyvaso may cause symptomatic hypotension (low blood pressure).
- Are pregnant or plan to become pregnant. It is not known if Tyvaso will harm your unborn baby. Women who can become pregnant should use effective birth control while taking Tyvaso.
- Are breast-feeding or plan to breast-feed. It is not known if Tyvaso passes into your breast milk.
It is important to tell your healthcare provider about all the medicines you may be taking, including
prescription and non-prescription medicines, vitamins, and herbal supplements, as they may affect your use
of Tyvaso by increasing the risk of side effects or decreasing effectiveness. Especially tell your healthcare
provider if you take any of these medicines:
Medicines that decrease blood clotting such as warfarin or heparin, as Tyvaso reduces the ability of your
blood to clot (coagulate), and increases your risk for bleeding if you are taking blood thinners
Diuretics (water pills), antihypertensives (medications used to treat high blood pressure or heart
disease), or other vasodilators (medications that lower blood pressure), as Tyvaso may increase your
risk for hypotension (low blood pressure).
Gemfibrozil such as Lopid (for high cholesterol) or rifampin such as Rimactane, Rifadin, Rifamate or
Rifater (for infection), as your Tyvaso dosage may need adjustment.
The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea,
reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the
possible side effects of Tyvaso. Tell your healthcare provider about any side effects that bother you or do
not go away. Your healthcare provider may be able to help you manage the side effects.
Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO
Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in
people who also take bosentan (an endothelin receptor antagonist, (ERA)) or sildenafil (a
phosphodiesterase-5 (PDE-5) inhibitor). Your ability to do exercise decreases 4 hours after taking Tyvaso.
The effects of Tyvaso are unknown in patients under 18 years of age.
Please see the Full Prescribing Information, Patient Package Insert, and the Tyvaso Inhalation System Instructions for Use manual.
For additional information about Tyvaso, visit www.tyvaso.com or call 1-877-UNITHER (1-877-864- 8437).
Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.
This information is provided for an informational purpose and is not intended as treatment advice. Patients should consult a healthcare professional for treatment advice.